Antonio Vega-Mateos

Antonio Vega-Mateos

Auto-generated profile, based on publicly available information

Antonio Vega-Mateos

Servicio de Hematología, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
PCPerla R. Colunga-Pedraza
Perla R. Colunga-Pedraza
HVHéctor A. Vaquera-Alfaro
Héctor A. Vaquera-Alfaro
ZGZulia Guzmán-Martínez
Zulia Guzmán-Martínez
MAMarion Carolina Alemán-Jiménez
Marion Carolina Alemán-Jiménez
AVAntonio Vega-Mateos
Antonio Vega-Mateos
DGDavid Gómez-Almaguer
David Gómez-Almaguer

1 May 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
HVHéctor A. Vaquera-Alfaro
Héctor A. Vaquera-Alfaro
JMJosé Emiliano Montelongo-Cepeda
José Emiliano Montelongo-Cepeda
AVAntonio Vega-Mateos
Antonio Vega-Mateos
AMAnahí Morales-Pedraza
Anahí Morales-Pedraza
HVHaydee Cristina Verduzco-Aguirre
Haydee Cristina Verduzco-Aguirre
PCPerla R. Colunga-Pedraza
Perla R. Colunga-Pedraza
PURPOSE: Blockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reductions on the basis of pharmacodynamic studies have been used to allow access to these drugs to patients with no further options because of economic constraints. In this study, we aimed to systematically review and assess evidence regarding the efficacy and safety of this adapted intervention. METHODS: An expert librarian designed and conducted a literature search in MEDLINE, Scopus, Web of Science, EMBASE, Cochrane Central, and clinicaltrials.gov. Screening was conducted in a title/abstract and full-text phase independently and in duplicate. Primary outcomes were overall survival, overall response rates (ORRs), and incidence of adverse events (AEs). Data extraction was performed independently and in duplicate as well. A qualitative synthesis was performed and reported in the results. RESULTS: Six studies investigated Nivo as an intervention, two Pembro, and 1 both therapies, with a total of 161 patients overall. One study had a single-arm prospective trial design and the rest a retrospective cohort design. ORR ranged from 66% to 100%, with complete response rates between 38% and 75%. The incidence of AEs was mostly high across all studies ranging from 27% to 93%, most of it composed of grade 1-2 AEs (27%-80%). No study reported health-related quality-of-life outcomes. CONCLUSION: Low-dose anti-PD1 immune checkpoint inhibitors have shown to be adequate candidates for testing of their efficacy in randomized trials and could improve access to these high-cost medications for patients with Hodgkin lymphoma both in LMICs and high-income countries.

2 November 2023 in Blood
Verified
Journal Article
Open access
HMHéctor A. Martínez-Espinosa
Héctor A. Martínez-Espinosa
NMNereida Méndez-Ramírez
Nereida Méndez-Ramírez
JPJulia Colunga Pedraza
Julia Colunga Pedraza
EFEli Fuentes-Chávez
Eli Fuentes-Chávez
RSRosario Salazar-Riojas
Rosario Salazar-Riojas
RSRoberto Solano-Texta
Roberto Solano-Texta
Disclosures. Gomez-Almaguer:Novartis: Honoraria; Janssen: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Gomez-De Leon:A